The NeoTYPE Endometrial Tumor Profile analyzes 38 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.
NGS (40 genes + 2 biomarkers): AKT1, APC, ARID1A, ATM, ATR, ATRX, BRAF, BRCA1, BRCA2, CDH1, EGFR, EPCAM, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, MTOR, MUTYH, NRAS, PDGFRA, PIK3CA, PIK3R1, PMS2, POLE, PTEN, PTPN11, SMAD4, SMARCA4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
FISH (2 FISH): MET, PTEN (tech-only available)
IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
The NeoTYPE Endometrial Tumor Profile characterizes primary or metastatic endometrial tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, and for patients with resistant disease to explore options in clinical trials.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. All slides can be packed at room temperature.
14 days; add 1-3 days if reflexed to NTRK NGS Fusion Profile